On November 16, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, reported the closing of an aggregate of $4.25 million fixed-price equity financings priced at-the-market, including a private placement led by its Chief Executive Officer and other insiders. The private placement totaled $1.25 million, or approximately 30% of the total financings, and was made to a limited number of accredited investors consisting primarily of directors and officers of the Company, including $750,000 from Medicus’ Executive Chairman and Chief Executive Officer. Approximately $3.0 million of the financing was conducted via a registered direct offering pursuant to the Company’s shelf registration statement on Form S-3 and a prospectus supplement. The investment reflects management’s and insiders’ support for the Company’s strategic direction, with CD228V, its investigational antibody-drug conjugate utilizing an established Vedotin platform, at the center of its precision oncology focus.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company also announced the exchange of $10.5 million of indebtedness held by Streeterville Capital, LLC ("Streeterville") for preferred shares. Together with the $4.25 million equity financings, and an additional approximately $350,000 of common shares sold via Medicus’ at-the-market program since September 30, 2026, the Company believes that the transactions have strengthened the Company’s shareholders’ equity above Nasdaq’s $2.5 million continued-listing threshold, and that, subject to Nasdaq confirmation, the Company has regained compliance in respect of Nasdaq rule 5550(b).
Maxim Group LLC acted as financial advisor to the Company in connection with the registered direct offering.
CEO-Led Equity Financing and Strategic Alignment
The $4.25 million fixed-price equity financing priced at-the-market includes $1.25 million of participation led by Company insiders, of which $750,000 is attributable to the CEO. The financing is intended to provide additional working capital to support the Company’s operating and development priorities, including the advancement of CD228V, and may also include the strengthening of the Company’s balance sheet through debt repayment. The Company views this insider participation as a demonstration of alignment with shareholders and conviction in its precision oncology-led direction. The registered direct offering was for 97,973 common shares plus pre-funded warrants to purchase up to 1,646,213 common shares, priced at-the-market at an effective price of $1.72 per share and the private placement was for 726,730 common shares, also priced at-the-market at $1.72 per share. The common shares issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and are restricted securities.
Certain directors and senior officers of the Company (collectively, the "Related Parties") purchased an aggregate of 616,272 common shares pursuant to the private placement (the "Related Party Participation"). Participation by the Related Parties in the private placement was considered a "related party transaction" pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the Related Party Participation pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as neither the fair market value of any securities issued to, nor the consideration paid by, the Related Parties exceeded 25% of the Company’s market capitalization (as defined in MI 61-101). The Company did not file a material change report relating to the Related Party Participation more than 21 days before the expected closing date of the private placement as the details of the Related Party Participation were not settled at such time and the Company wished to close the private placement on an expedited basis for sound business reasons.
Streeterville Debt Exchange and Shareholders’ Equity
Streeterville exchanged $10.5 million of outstanding indebtedness under the Company’s Secured Promissory Notes for 105,000 preferred shares at an issue price of $100 per share. The preferred shares are non-voting, except as required by law, and non-convertible into common shares. They carry an 8% cumulative annual dividend payable in kind and are redeemable at the Company’s option, with no holder redemption right. The exchange did not generate cash proceeds; any indebtedness not exchanged remains outstanding.
Early Warning Disclosure
In connection with the private placement, Dr. Raza Bokhari, company’s Executive Chairman and CEO acquired beneficial ownership of, or control or direction over, an aggregate of 436,046 common shares of the Company indirectly through RBx Capital LP, an entity controlled by Dr. Bokhari.
Prior to the completion of the transactions described herein, Dr. Bokhari had beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 74,687 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 3.8% of the issued and outstanding common shares on a non-diluted basis and approximately 5.1% of the issued and outstanding common shares on a partially diluted basis. Following the transactions described herein, Dr. Raza Bokhari has beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 510,733 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 18.3% of the issued and outstanding common shares on a non-diluted basis and approximately 19.1% of the issued and outstanding common shares on a partially diluted basis.
Dr. Bokhari acquired the common shares for investment purposes. Dr. Bokhari may seek to increase or decrease his investment, directly or indirectly in the Company through the market, privately or otherwise, depending on market conditions or any other relevant factors, or may in the future develop plans or intentions relating to any of the other actions listed in (a) through (k) of Form 62-103F1 – Required Disclosure Under the Early Warning Requirements.
Dr. Bokhari’s business address is 300 Conshohocken State Road, Suite 200, West Conshohocken, PA 19428, United States.
For the purposes of this news release and early warning disclosure, the pro forma number and percentage of outstanding common shares owned and controlled by Dr. Bokhari following completion of the transactions described herein is based on 2,788,106 outstanding common shares following the completion of the private placement and the registered direct offering.
This portion of this news release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. An early warning report will be filed by Dr. Bokhari on SEDAR+ (www.sedarplus.ca) under the Company’s issuer profile. Persons who wish to obtain a copy of the early warning report to be filed by Dr. Bokhari may obtain a copy of such report from SEDAR+ (www.sedarplus.ca) or by contacting Carolyn Bonner, President and CFO of the Company at (610) 636-0184 or [email protected].
(Press release, Medicus Pharma, NOV 16, 2026, View Source [SID1234674794])